search
close_mark

Julianna Pherarolis

Julianna Pherarolis

25 Jun, 2025

ā€œI am incredibly satisfied with the work Celegence has done thus far. They communicate well and receive feedback well. I find the team I have been assigned incredibly easy to work with, friendly, and people I genuinely look forward to speaking with once a week.ā€

Dr. Carlos Munoz-Viveros
Read Now

Other Related Articles

Devices Incorporating Tissues or Cells of Animal or Human Origin, or Their Derivatives: Data Expectations Under EU MDR
Blog Medical Devices

Devices Incorporating Tissues or Cells of Animal or Human Origin, or Their Derivatives: Data Expectations Under EU MDR

13 May, 2026

Nitrosamine Control Insights: Clarity and Control in EU Risk Assessment
Blog Pharmaceutical

Nitrosamine Control Insights: Clarity and Control in EU Risk Assessment

07 May, 2026

PMCF Under MDR: When is a Healthcare Professional Survey Approach Justifiable?
Blog Medical Devices

PMCF Under MDR: When is a Healthcare Professional Survey Approach Justifiable?

29 Apr, 2026

Dental Medical Devices: Special Considerations for Clinical Evaluation Under EU MDR
Blog Medical Devices

Dental Medical Devices: Special Considerations for Clinical Evaluation Under EU MDR

22 Apr, 2026

MDR Article 117: What It Means ā€” And How We Help You Get Ahead
Blog Medical Devices

MDR Article 117: What It Means ā€” And How We Help You Get Ahead

16 Apr, 2026

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative
Blog Pharmaceutical

Heavy Metals in Pharmaceuticals: A Critical Quality and Safety Imperative

10 Apr, 2026

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era
Blog Pharmaceutical

EMA Roadmap Update: PMS Capabilities and the End of the Legacy Era

01 Apr, 2026

Expanded Access Approval : Balancing Urgency and Oversight in Regulatory Affairs
Blog Pharmaceutical

Expanded Access Approval : Balancing Urgency and Oversight in Regulatory Affairs

26 Mar, 2026

View All